What the investigators compared
Researchers assessed GH secretion in 17 older men using a GHRH–GHRP-6 stimulation test and compared responses with cognitive testing and electrical brain measurements. GH responses correlated with selected measures involving attention, response speed and short-term memory. The study examined associations; it did not test a long-term sermorelin treatment. [1]
A stimulation-test response answers a different question from whether medication will improve a symptom. This distinction matters when a laboratory evaluation is presented as if it identifies both the cause of brain fog and the treatment that will fix it.
The direction of explanation remains open
Our interpretation is that correlated measurements do not establish a one-way causal chain. Other characteristics could contribute to both results, and the study design does not tell us what would happen if a clinician changed one of them. A physiological relationship can be real without being a validated treatment-selection rule.
For example, a person with a stronger hormone response may also perform differently on a task for reasons not isolated by the experiment. To show that a test predicts treatment benefit, researchers would need to examine that prediction prospectively in an appropriate intervention study. That is an additional question, not a detail already answered by a correlation.
Cognitive testing is not a single score for daily life
The associations concerned selected tasks. [1] A research task can isolate a component of attention or processing more cleanly than everyday experience, but that precision narrows the claim. The result should not become an assertion that a low hormone response explains every kind of forgetfulness or mental fatigue.
Readers can make the consultation more useful by describing concrete examples of what has changed. Difficulty sustaining attention, finding words and remembering appointments are different concerns. A broad phrase such as hormone optimization can obscure those differences before an appropriate evaluation has even begun.
Where intervention evidence fits
Compare this association study with the randomized tesamorelin cognition trial. The studies ask different questions, and neither should be treated as a direct test of a modern compounded sermorelin program. Our earlier GHRH cognition overview adds another intervention context.
If a clinic uses a stimulation result to support treatment, ask what diagnosis is being evaluated and what evidence connects that result to the proposed benefit. A clear answer should distinguish diagnostic reasoning, research associations and the evidence for the actual prescription. That separation protects a useful laboratory assessment from being overinterpreted.
If a test is offered as a prediction tool, ask whether its predictive accuracy was evaluated in people receiving the same treatment. Demonstrating a correlation between two baseline measurements is a different validation task from predicting a future treatment response.